FDA Approves ATOMOXETINE HYDROCHLORIDE — Advagen Pharma Ltd.

# FDA Approves Advagen Pharma's Atomoxetine Hydrochloride for Oral Administration Advagen Pharma Ltd. has received FDA approval for its atomoxetine hydrochloride oral formulation (NDA220320), positioning the company to capture market share in the competitive ADHD treatment segment dominated by established players. The approval could strengthen Advagen's portfolio in attention deficit hyperactivity disorder therapeutics, though market impact will depend on pricing strategy and formulary acceptance relative to existing atomoxetine alternatives.